Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Senior Management
Scientific Advisory Board
Corporate Governance
Programs
Xolatryp
Myocardial Ischemia and Arrhythmia Control
Stroke
Traumatic Brain Injury
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
ASX Announcements
Filter by Year:
2026
2025
2024
2023
2022
2021
2020
29-May-2026
Nyrada Receives A$2.455M R&D Tax Incentive Rebate
25-May-2026
Cleansing Statement
25-May-2026
Application for quotation of securities - NYR
21-May-2026
Upcoming Expiry of Unlisted Options
20-May-2026
Xolatryp Enhances Anthracycline Anti-Tumour Efficacy
19-May-2026
Trading Halt
19-May-2026
Pause in Trading
19-May-2026
Nyrada Receives Notice of Allowance for Xolatryp US Patent
22-Apr-2026
First Site Activated in Nyradas PROTECT-MI Phase IIa Trial
15-Apr-2026
Quarterly Activities Report and Appendix 4C
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
Next
